Lataa...
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1) and γ-secretase endoproteolysis. Alternative APP cleavage by α-...
Tallennettuna:
| Julkaisussa: | Transl Psychiatry |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group UK
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7026402/ https://ncbi.nlm.nih.gov/pubmed/32066688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41398-020-0709-x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|